CHICAGO — At the Ophthalmology Innovation Summit here, TearScience president and CEO Joseph Boorady talks about first diagnosing meibomian gland dysfunction with the company’s LipiScan technology, then treating dry eye symptoms caused by MGD with LipiFlow. He said that recent study results showed a “powerful” sustained effect of a single LipiFlow treatment on dry eye symptoms, lasting up to 1 year.
CHICAGO — At the Ophthalmology Innovation Summit here, chairman and chief executive officer of Aerie Pharmaceuticals Vincente Anido Jr., PhD, says “spectacular” progress has been made with regard to two of the company’s leading glaucoma products. In September, the company filed a new drug application for Rhopressa (netarsudil), a rho kinase inhibitor that acts on the trabecular meshwork, and “very successful” phase 3 trial results were reported for Roclatan, a product combining Rhopressa and latanoprost.
CHICAGO — At the Ophthalmology Innovation Summit here, Jeffrey D. Marrazzo, chief executive officer of Spark Therapeutics, discusses a new initiative by Spark to provide physicians and patients access to genetic testing for more than 30 genes linked to certain forms of inherited retinal diseases. The initiative is called the Identify Your Inherited Retinal Disease, or ID YOUR IRD.
Refractive prediction error is significantly less myopic in older patients, decreasing by approximately 0.06 D per decade, a new study showed. Medscape Medical News
Refractive prediction error is significantly less myopic in older patients, decreasing by approximately 0.06 D per decade, a new study showed. Medscape Medical News
Researchers from the Icahn School of Medicine at Mount Sinai have been awarded a $10 million from the National Cancer Institute to explore the cellular and molecular mechanisms of acute graft-versus-host disease (GVHD), a common side effect that occurs…